Christine Rudolph
Munich, BY, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Early Symptomatic Improvement Is Informing Long-Term Quality-of-Life Outcomes with Filgotinib Treatment in Ulcerative Colitis: A Post Hoc Analysis of the SELECTION and SELECTIONLTE Trials.
Journal: Inflammatory intestinal diseases
Published: February 20, 2026
Association between endo-histological outcomes and colonic mucosal transcriptomic profiles in patients with ulcerative colitis receiving filgotinib.
Journal: Journal of Crohn's & colitis
Published: January 22, 2026
Safety and efficacy of long-term filgotinib treatment in Japanese patients with ulcerative colitis: an interim subgroup analysis of the SELECTION long-term extension study.
Journal: Crohn's & colitis 360
Published: September 10, 2025
Ulcerative colitis disease severity affects the speed of symptom relief under filgotinib treatment: a post hoc analysis of the phase 2b/3 SELECTION study.
Journal: Intestinal research
Published: October 23, 2024
Major adverse cardiovascular, thromboembolic and malignancy events in the filgotinib rheumatoid arthritis and ulcerative colitis clinical development programmes.
Journal: RMD open
Published: September 23, 2024
Long-term safety and efficacy of filgotinib for the treatment of moderately to severely active ulcerative colitis: Interim analysis from up to 4 years of follow-up in the SELECTION open-label long-term extension study.
Journal: Alimentary pharmacology & therapeutics
Published: February 20, 2024
Residual Disease Burden Among European Patients With Inflammatory Bowel Disease: A Real-World Survey.
Journal: Inflammatory bowel diseases
Published: November 29, 2023
Integrated safety analysis of filgotinib for ulcerative colitis: Results from SELECTION and SELECTIONLTE.
Journal: Alimentary pharmacology & therapeutics
Published: April 13, 2023
Efficacy of Filgotinib in Patients with Ulcerative Colitis by Line of Therapy in the Phase 2b/3 SELECTION Trial.
Journal: Journal of Crohn's & colitis
Published: March 17, 2023
Biosimilar Retacrit® (epoetin zeta) in the treatment of chemotherapy-induced symptomatic anemia in hematology and oncology in Germany (ORHEO) - non-interventional study.
Journal: OncoTargets and therapy
Published: March 11, 2017
Compatibility of Biosimilar Filgrastim with Cytotoxic Chemotherapy during the Treatment of Malignant Diseases (VENICE): A Prospective, Multicenter, Non-Interventional, Longitudinal Study.
Journal: Advances in therapy
Published: August 10, 2016
Showing 1-11 of 11
Last Updated: 09/26/2026